ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NPH

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
TSXV:NPH TSX Venture Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

NUVA Announces Licensing Agreements for 48 Generic Drugs for Canadian Markets

16/04/2014 5:48pm

Marketwired


Vanc Pharmaceuticals Inc. (TSXV:NPH)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Vanc Pharmaceuticals Inc. Charts.
NUVA Announces Licensing Agreements for 48 Generic Drugs for Canadian Markets

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Apr 16, 2014) - NUVA PHARMACEUTICALS INC. (the "Company" or "NUVA") (TSX-VENTURE:NPH) (OTCQB:NUVPF) is pleased to announce that it has signed Cross Referencing Agreements (the "CRAs") for prescription generic products for Canadian markets. These agreements cover 48 prescription generic products and are for acute and chronic diseases.

The company has signed CRAs with three large pharmaceutical companies for multiple products in the prescription generic drug lines. NUVA will market and sell these new product lines under its own label.

NUVA is in the process of securing a Drug Establishment License (the "DEL") from Health Canada. Upon receipt of the DEL, NUVA will start filing for regulatory approval of these products with Health Canada. NUVA will also initiate ordering, packaging and art work related processes for these generic products. NUVA expects to build its "NUVA" label Generic portfolio for the Canadian Market apart from the "NUVA" range of Over-the-Counter products.

On behalf of:

NUVA PHARMACEUTICALS INC.

Jamie Lewin, Director and CFO

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves NUVA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. NUVA generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to NUVA as of the date of this release, and NUVA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of NUVA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

NUVA Pharmaceuticals Inc.Jamie LewinDirector and CFOjlewin@nuvapharm.com

1 Year Vanc Pharmaceuticals Inc. Chart

1 Year Vanc Pharmaceuticals Inc. Chart

1 Month Vanc Pharmaceuticals Inc. Chart

1 Month Vanc Pharmaceuticals Inc. Chart

Your Recent History

Delayed Upgrade Clock